ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vasculitis"

  • Abstract Number: 2561 • ACR Convergence 2023

    The Prognostic Value of the “2022 ACR/EULAR Classification Criteria for Giant Cell Arteritis”: Data from the Italian Society of Rheumatology Vasculitis Study Group

    Alessandro Tomelleri1, Corrado Campochiaro2, Francesco Muratore3, Sara Monti4, Nicola Farina5, Chiara Marvisi6, Elena Galli7, Alessandra Milanesi8, Naomi Viapiana5, Alvise Berti9, Roberto Bortolotti9, Milena Bond10, Roberto Padoan11, Mara Felicetti9, Franco Schiavon12, Carlotta Nannini13, Fabrizio Cantini13, Alessandro Giollo14, Maurizio Rossini15, Edoardo Conticini16, Bruno Frediani17, Fabrizio Conti18, Roberta Priori18, Marco Sebastiani19, Giulia Cassone20, Luca Quartuccio Quartuccio21, Elena Treppo22, Silvano Bettio23, Ariela Hoxha24, Marco Lovisotto24, Giacomo Emmi25, irene mattioli26, Pietro Leccese27, Roberto F. Caporali28, Lorenza Maria Argolini29, Rosario Foti30, Elisa Visalli30, Michele Colaci31, Carlomaurizio Montecucco32, Lorenzo Dagna33 and Carlo Salvarani34, 1Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, 2IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, 3IRCCS di Reggio Emilia, Reggio Emilia, Italy, 4Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, 5IRCCS San Raffaele Hospital, Milan, Italy, 6IRCCS di Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, 7Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, 8Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, 9Santa Chiara Hospital of Trento, Trento, Italy, 10Azienda sanitaria dell'Alto Adige, Merano, Italy, 11Department of Medicine DIMED, University of Padova, Padova, Italy, 12University of Padova, Padova, Italy, 13Santo Stefano Hospital Prato, Prato, Italy, 14Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy, 15Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy, 16Tallaght University Hospital, Dublin, Ireland, 17University of Siena, Siena, Italy, 18University of Rome La Sapienza, Rome, Italy, 19Azienda Policlinico di Modena, Modena, Italy, 20University of Modena and Reggio Emilia, Modena, Italy, 21Rheumatology Division, Department of Medicine, University of Udine, Udine, Italy, 22Physician, Moimacco, Italy, 23University of Padua, Treviso, Italy, 24San Bortolo Hospital of Vicenza, Vicenza, Italy, 25University of Florence, Florence, Italy, 26University of Florence, Firenze, Italy, 27Regional Hospital San Carlo, Potenza, Italy, 28Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, 29ASST Gaetano Pini, Milano, Italy, 30AOU San Marco, Catania, Catania, Italy, Catania, Italy, 31University of Catania, Catania, Italy, 32Unità Operativa e Cattedra di Reumatologia, IRCCS Policlinico S Matteo, Pavia, Italy, 33Ospedale San Raffaele, Milano, Italy, 34Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy

    Background/Purpose: The 2022 classification criteria for giant cell arteritis (GCA) have been recently published. The aim of this study is to investigate whether the score…
  • Abstract Number: 0044 • ACR Convergence 2023

    Aberrant Mevalonate Metabolite Farnesyl Pyrophosphate-Induced Neutrophil Hyperactivation in Behçet’s Disease Pathogenesis

    Menghao Zhang1, Na Kang2, Xin Yu1, Wanli Liu2 and Wenjie Zheng1, 1Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, 2Beijing Key Lab for Immunological Research on Chronic Diseases, School of Life Sciences, Institute for Immunology, Tsinghua University, Beijing, China

    Background/Purpose: Behçet’s disease (BD) is a chronic vasculitis characterized by polymorphonuclear neutrophils (PMNs) hyperactivation with unknown etiology. The over-productions of neutrophil extracellular traps (NETs) and…
  • Abstract Number: 0697 • ACR Convergence 2023

    Alterations in Composition and Function of Gut Microbiota in Patients with Large-Vessel Vasculitis

    Adam Mayer1, Weiming Hu2, Kyle Bittinger2, Rui Liang3, Naomi Amudala3, Shubhasree Banerjee3, Peter Merkel3 and Rennie Rhee3, 1University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, PA

    Background/Purpose: The gut microbiome has a critical role in immune homeostasis and there is growing interest in understanding the relationship between the microbiome and autoimmunity.…
  • Abstract Number: 0747 • ACR Convergence 2023

    Clinical Phenotype of Patients with Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica

    Sharon Cowley1, Colm Kirby2, Patricia Harkins3, Richard Conway4 and David Kane5, 1Tallaght University Hospital, Dublin, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Ireland, 3St James's Hospital, Dublin, Ireland, 4Trinity College Dublin, Dublin, Ireland, 5Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland

    Background/Purpose: It has been reported that more than a quarter of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). It remains unclear…
  • Abstract Number: 1538 • ACR Convergence 2023

    Large Vessel Involvement in Antineutrophil Cytoplasmic Antibody- Associated Vasculitis: A Single Center Experience over Two Decades

    Mahmut Kaymakci1, Mohanad Elfishawi1, Hannah Langenfeld2, Andrew Hanson2, Cynthia Crowson1, Melanie Bois1, Umar Ghaffar1, Ulrich Specks1, Matthew Koster1 and Kenneth Warrington1, 1Mayo Clinic, Rochester, MN, 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN

    Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is currently categorized under the small vessel vasculitides and includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA),…
  • Abstract Number: 1573 • ACR Convergence 2023

    Inpatient Prevalence and Comorbidity of Takayasu’s Arteritis: Nationwide Inpatient Sample 2016-2020

    Husam el Sharu1, Sukhvir Singh1, Omar Alwahadneh2, Mohammad Alqaisieh3 and Laksmi Subramanian1, 1East Carolina University, Greenville, NC, 2Carle Foundation Hospital, Urbana, IL, 3Hamilton Medical Center, Dalton, GA

    Background/Purpose: Takayasu’s Arteritis (TAK) is a granulomatous large-vessel vasculitis that affects the aorta and its branches, and it is more commonly observed in women. We…
  • Abstract Number: 2381 • ACR Convergence 2023

    ANCA-associated Vasculitis and Renal Disease in a Multidisciplinary Outpatient Clinic in Northern Spain

    Salma Al Fazazi1, Fabricio Benavides2, Vanesa Calvo Río3, maria rodriguez Vidriales2, clara escagedo Cagigas2, monica renuncio garcia2, luis martin penagos4 and Ricardo Blanco5, 1Hospital Universitario Puerta Del Mar, Cádiz, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Valdecilla Hospital, Santander, Spain, 4Division of Nephrology, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-DIVAL, Santander, Spain, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: The severity of clinical features and outcomes in previous series of patients reported with renal disease related to ANCA-associated vasculitis (AAV) vary greatly, probably…
  • Abstract Number: 2415 • ACR Convergence 2023

    Giant Cell Arteritis Is Associated with Worse Hospital Outcomes in Aortic Aneurysm/Dissection Hospitalizations: A Nationwide United States Population-Based Study

    Artem Minalyan1, Christopher Hino1, Emily He1, Osahon Idolor2, Chinenye Osuorji3, Nneka Chukwu4, Ehizogie Edigin1 and Vaneet Sandhu5, 1Loma Linda University Health, Loma Linda, CA, 2Piedmont Athens Regional Hospital, Atlanta, GA, 3Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 4Nuvance Health Internal Medicine Residency, Poughkeepsie, NY, 5Loma Linda University, Loma Linda, CA

    Background/Purpose: Giant Cell Arteritis (GCA) is a known risk factor for Aortic Aneurysm/Dissection (AAD). However, it is unclear if patients with GCA have worse hospital…
  • Abstract Number: 2562 • ACR Convergence 2023

    Immune Checkpoint Inhibitors-Induced Large Vessel Vasculitis: Data from a Multicenter Study

    Adrien Cottu1, Alessandro Tomelleri2, Corrado Campochiaro3, Alexandra Forestier4, Jérémie Dion5, Milena Bond6, Ariane Laparra-ramakichenin7, Aline Gury8, Xavier Savary9, Robin Dhote10, Albrecht Betrains11, Laurence Bouillet12, Eric Liozon13, Eva Bories14, Arthur Petitdemange1, Paul Legendre15, Benjamin Crichi16, Philippe Kerschen17, Lucie Carneiro-Esteves18, Lucile Grange18 and Benjamin Terrier19, 1Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 2Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, 3IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, 4Department of Medical Oncology, Centre Oscar Lambret, Lille, France, 5Internal Medicine Department, Toulouse University Hospital, Toulouse, France, 6Azienda sanitaria dell'Alto Adige, Merano, Italy, 7Department of Therapeutic Innovations and Early Trials, Gustave Roussy, Université Paris-Saclay, Villejuif, France, 8Department of Internal Medicine, Arras GHAT, Arras, France, 9Department of Internal Medicine, Brest CHU Hospital, Brest, France, 10Department of Internal Medicine, Centre Hospitalier Avicenne, Bobigny, France, 11Department of General Internal Medicine, University Hospitals Leuven, Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium, 12Internal medicine department, Grenoble University Hospital, Grenoble, France, 13Department of Internal Medicine, University Hospital of Limoges, Limoges Cedex, Limoges, France, 14Department of Internal Medicine, Purpan CHU Hospital, Toulouse, France, 15Department of Clinical Immunology, Centre hospitalier du Mans, Le Mans, France, 16Department of Internal Medicine, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 17Department of Neurology, Luxembourg Hospital Center, Luxembourg City, Luxembourg, 18Department of Internal Medicine, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France, 19Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have dramatically improved the prognosis for many cancers. The therapeutic effect of ICIs is based on their ability to release…
  • Abstract Number: 031 • 2023 Pediatric Rheumatology Symposium

    Multisystem Inflammatory Syndrome in Children Phenotypes Vary Between SARS-CoV-2 Variants

    Greta Mastrangelo1, Ellen Go2, Paul Tsoukas2, Hua Lu3, Amy Xu2, Arthur Hoi Hin Cheng2 and Rae Yeung4, 1The Hospital of Sick Children,Department of Paediatrics, University of Toronto, Division of Rheumatology, Toronto, ON, Canada, 2The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, 3The Hospital for Sick Children, Toronto, ON, Canada, 4The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a serious complication associated with COVID-19, presenting as a hyperinflammatory disorder characterized by fever and multiorgan dysfunction.…
  • Abstract Number: 045 • 2023 Pediatric Rheumatology Symposium

    Patient Reported Outcomes in Pediatric Vasculitis

    Clare Peckenpaugh1, Aimee Hersh2, CJ Inman1, Sara Stern1, Erin Treemarcki2, Peter Merkel3 and Karen James1, 1University of Utah Department of Pediatrics, Salt Lake City, UT, 2University of Utah, Salt Lake City, UT, 3University of Pennsylvania, Philidelphia, PA

    Background/Purpose: Vasculitis is a group of multisystem, often relapsing diseases that can affect patients through disease activity, damage, and treatment toxicity. Vasculitis in adults often…
  • Abstract Number: 060 • 2023 Pediatric Rheumatology Symposium

    Are the Levels of Cytokines Good Biomarkers for Smoldering Disease Activity in Childhood-Takayasu Arteritis?

    Gleice Clemente1, Maria Teresa Terreri2, Bruno Gualano3, Clovis Silva4 and Alexandre Wagner De Souza1, 1Universidade Federal de São Paulo, São Paulo, Brazil, 2UNIFESP, São Paulo, Brazil, 3Universidade de São Paulo, São Paulo, 4Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Biomarkers for disease activity in adult Takayasu arteritis (TA) have been studied exhaustively, but there are inconsistencies among the studies (1). Childhood-TA (c-TA) differs…
  • Abstract Number: 061 • 2023 Pediatric Rheumatology Symposium

    Variation in Treatment Approaches to IVIG- Refractory Kawasaki Disease (KD) Among Pediatric Rheumatologists: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Treatment of Refractory KD Survey

    Daniel Ibanez1, Bianca Lang2, Ali Yalcindag3, Linda Wagner-Weiner4, Julia Shalen5, Kenneth Schikler6, Shoghik Akoghlanian7, Hulya Bukulmez8, Kristen Hayward9, Sivia Lapidus10, Andrea Ramirez11, Robert Sundel1, Cagri Yildirim-Toruner12 and CARRA Registry Investigators13, 1Boston Children's Hospital, Boston, MA, 2Dalhousie University - Halifax, Halifax, NS, Canada, 3Hasbro Children's Hospital, Milton, MA, 4The University of Chicago, Chicago, IL, 5Johns Hopkins University, Baltimore, MD, 6University of Louisville School of Medicine Norton Children's Hospital, Louisville, KY, 7Nationwide Children's Hospital, Columbus, OH, 8MetroHealth Medical Center, Case Western Reserve, Cleveland, OH, 9Seattle Children's Hospital/University of Washington School of Medicine, Seattle, WA, 10Department of Pediatrics, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, 11Baylor College of Medicine, Houston, TX, 12Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 13CARRA, Washington, DC

    Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in children in North America. Initial treatment with IVIG has significantly reduced the…
  • Abstract Number: 071 • 2023 Pediatric Rheumatology Symposium

    Clinical Manifestations and Management of Takayasu Arteritis: A Single Center Pediatric Cohort

    Ana Luiza Altaffer1, Alvaro Orjuela2 and Marietta De Guzman2, 1Texas Children's Hospital, Houston, TX, 2Baylor College of Medicine, Texas Children's Hospital, Houston, TX

    Background/Purpose: Takayasu arteritis (TA) is a rare granulomatous vasculitis that affects large vessels, including the aorta, its major branches, and the pulmonary artery. Data on…
  • Abstract Number: L17 • ACR Convergence 2022

    Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis

    Robert Maughan1, Andrew Porter1, Chanaka Dahanayake2, Claudia Ianonne1, Ritu Alapat1, Charis Pericleous1, Taryn Youngstein3 and Justin Mason1, 1Imperial College London, London, United Kingdom, 2Barts Health NHS Trust, London, United Kingdom, 3Imperial NHS Trust, London, United Kingdom

    Background/Purpose: Immunosuppression in Takayasu Arteritis (TA) reduces the risk of arterial damage and disease progression. However, long-term use of glucocorticoids (GC) and other immunosuppressants carries…
  • « Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • …
  • 41
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology